Director - Science Communications and Engagement, Late CVRM

Gaithersburg, MD (On-site)

$147K/yr – $220K/yrDirector/Executive5+ years expFull time

Posted 4 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Lead internal communications for AstraZeneca\u2019s Late CVRM program, shaping strategy and stakeholder engagement across disease areas and projects.

  • Define and execute the internal communications strategy for Late CVRM
  • Must-have: 5+ years in pharma/biotech with science storytelling
  • Collaborate with SVP and leadership to align strategy across global teams

Job Description

Responsibilities

  • Define and implement the internal communication strategy .
  • Work closely with the Senior Vice President of Late CVRM and Head of Business Planning & Operations to develop content and materials for internal and external meetings, conferences , as well as key presentations.
  • Define and implement the internal communications and engagement strategy for Late CVRM, aligning with key stakeholders across AstraZeneca.
  • Liaise with the Late CVRM leadership team to develop strategic communication plans for disease areas and projects.
  • Contribute to monthly reports, town halls, and presentations for the AstraZeneca Board, ensuring the effective communication of our CVRM story.
  • Deliver high-quality, engaging events and broadcasts (e.g., town halls) to bring the Late CVRM narrative to life.
  • Drive the development and communication of science, disease area, and project stories to showcase our innovative science and research, both internally and externally.
  • Facilitate the creation of relevant content for the Late CVRM internal website and support the communication of scorecard updates.
  • Foster a culture of community building and best practice sharing within the Late CVRM team.

Requirements

  • BS, Master's or PhD in a scientific discipline within the life sciences
  • Minimum of 5 years of experience in the pharmaceutical or biotech industry
  • Exceptional interpersonal and communication skills, with the ability to effectively communicate science and influence both internal and external stakeholders, including senior management
  • Passion for scientific communication and a talent for translating complex information into clear, compelling narratives fit for the audience.
  • Demonstrated ability to engage, influence, and collaborate across organizational boundaries with a delivery-focused, problem-solving mindset
  • Comprehensive understanding of the pharmaceutical drug discovery and development process
  • In-depth scientific knowledge in the CVRM therapeutic area
  • Excellent written and verbal communication skills in English
  • Agile and adaptable, with a keen eye for detail and a focus on delivering high-quality work
  • Collaborative spirit and a proven ability to work effectively in a global, matrix research environment

Benefits

  • Benefits offered included a qualified retirement program [401(k) plan]; paid vacation and holidays; paid leaves; and, health benefits including medical, prescription drug, dental, and vision coverage in accordance with the terms and conditions of the applicable plans.
AstraZeneca logo

AstraZeneca

4.0 Glassdoor

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.Community Guidelines: bit.ly/2MgAcio

Founded in 1999
Cambridge, England, GBR
77K employees (4,201 in marketing)
78% recommend to a friend
89% CEO approval

Traffic Signals

Monthly Visitors
1.3M
Monthly Google Ads Budget
$3.7K
Traffic Source Mix
Search
45.1%
Direct
42%
Referral
9.3%
Social
2.6%
Paid
0.9%

Headcount Trend

Current headcount: ~76.8K

Marketing Team

Marketing Team Size
3,642 (5% of company)
Median Career Experience
15 years
Median Tenure
5.3 years
Marketing Roles Posted (Last 30 Days)
18

Funding

Total Funding
$7.3B
Last Raise
$2B
Post IPO Debt, 19 days ago

Funding History

  • Feb 2026
    Post IPO Debt • $2B
  • Jul 2024
    Post IPO Debt • $1.5B
  • Feb 2023
    Post IPO Debt • $2.3B

Recent News